Therapeutics in Heart Failure: Is HFpEF Really the Target?

Time: 9:30 am
day: Day One


  • Status report on therapeutics in HFpEF: comparison with HFrEF and lessons from SGLT2i’s
  • Stratifying patients with HFpEF: Which phenotype? Which disease?
  • Targeting the treatment population with consideration of metabolic CV disease.
  • Implications for clinical trial design.